Financial News

Alnylam Pharmaceuticals (NQ: ALNY )

129.56 USD -1.61 (-1.23%)

Official Closing Price Updated: 4:06 PM EST, Dec 4, 2020 Add to My Watchlist

Price and Volume

Volume	320,500
Open	130.62
Bid (Size)	120.58 (1)
Ask (Size)	131.98 (2)
Prev. Close	131.17
Today's Range	127.25 - 132.07
52wk Range	84.97 - 167.33
Shares Outstanding	100,522,411
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels

December 03, 2020

PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™...

Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)

December 03, 2020

Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Alnylam® Pharmaceuticals as a limited distribution partner for OXLUMO™ (lumasiran)....

Performance

YTD	+12.06%	+12.06%
1 Month	-7.12%	-7.12%
3 Month	+5.48%	+5.48%
6 Month	+1.54%	+1.54%
1 Year	+4.29%	+4.29%

More News

Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 03, 2020

Are These The Best Biotech Stocks To Watch Right Now? 3 To Consider As Pfizer’s Vaccine Rollout Begins

December 02, 2020

Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference

November 25, 2020

Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing S

November 24, 2020

Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Ped

November 24, 2020

Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups

November 19, 2020

Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

November 13, 2020

Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity

November 05, 2020

Is The FDA Still Approving Drugs During the Pandemic?

Today 11:06 EST

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Financial News

Alnylam Pharmaceuticals (NQ: ALNY )

Price and Volume

Top News

Performance

More News

Popular Pages